Last reviewed · How we verify
FTC/TDF + EFV or LPV/R +T20
FTC/TDF + EFV or LPV/R +T20 is a Antiretroviral combination therapy (NRTI + NNRTI/PI + fusion inhibitor) Small molecule drug developed by French National Agency for Research on AIDS and Viral Hepatitis. It is currently in Phase 3 development for HIV-1 infection (treatment-naive or treatment-experienced patients).
This is a combination antiretroviral regimen that suppresses HIV replication through multiple mechanisms: nucleoside reverse transcriptase inhibition, non-nucleoside reverse transcriptase inhibition or protease inhibition, and fusion inhibition.
This is a combination antiretroviral regimen that suppresses HIV replication through multiple mechanisms: nucleoside reverse transcriptase inhibition, non-nucleoside reverse transcriptase inhibition or protease inhibition, and fusion inhibition. Used for HIV-1 infection (treatment-naive or treatment-experienced patients).
At a glance
| Generic name | FTC/TDF + EFV or LPV/R +T20 |
|---|---|
| Sponsor | French National Agency for Research on AIDS and Viral Hepatitis |
| Drug class | Antiretroviral combination therapy (NRTI + NNRTI/PI + fusion inhibitor) |
| Target | HIV reverse transcriptase, HIV protease, HIV gp41 fusion protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
FTC/TDF provides dual nucleoside reverse transcriptase inhibition to block viral RNA-to-DNA conversion. EFV (efavirenz) is a non-nucleoside reverse transcriptase inhibitor that further blocks this step, while LPV/R (lopinavir/ritonavir) is a protease inhibitor combination that prevents viral protein maturation. T20 (enfuvirtide) is a fusion inhibitor that blocks HIV entry into CD4+ cells. These agents work synergistically to suppress viral replication through complementary mechanisms.
Approved indications
- HIV-1 infection (treatment-naive or treatment-experienced patients)
Common side effects
- Nausea
- Diarrhea
- Rash
- Lipodystrophy
- Hepatotoxicity
- Injection site reactions (T20)
- CNS effects (efavirenz)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FTC/TDF + EFV or LPV/R +T20 CI brief — competitive landscape report
- FTC/TDF + EFV or LPV/R +T20 updates RSS · CI watch RSS
- French National Agency for Research on AIDS and Viral Hepatitis portfolio CI
Frequently asked questions about FTC/TDF + EFV or LPV/R +T20
What is FTC/TDF + EFV or LPV/R +T20?
How does FTC/TDF + EFV or LPV/R +T20 work?
What is FTC/TDF + EFV or LPV/R +T20 used for?
Who makes FTC/TDF + EFV or LPV/R +T20?
What drug class is FTC/TDF + EFV or LPV/R +T20 in?
What development phase is FTC/TDF + EFV or LPV/R +T20 in?
What are the side effects of FTC/TDF + EFV or LPV/R +T20?
What does FTC/TDF + EFV or LPV/R +T20 target?
Related
- Drug class: All Antiretroviral combination therapy (NRTI + NNRTI/PI + fusion inhibitor) drugs
- Target: All drugs targeting HIV reverse transcriptase, HIV protease, HIV gp41 fusion protein
- Manufacturer: French National Agency for Research on AIDS and Viral Hepatitis — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection (treatment-naive or treatment-experienced patients)